Oncology

1922–1951 · 1 of 7

Multimodal Oncology Emergence

1922–1951

Multimodal Oncology Emergence

Contemporary themes

During this period oncology consolidated multiple treatment modalities, with radium and external beam radiotherapy broadening clinical options, surgical classifications aligning with prognosis, and early hormonal manipulation for prostate cancer alongside nascent chemotherapy efforts, signaling a shift toward combined modality management. Pathology-led cancer research emphasized tumor biology, histologic criteria, and mapping of metastasis, foreshadowing unified staging concepts and treatment planning. Translational work employed animal models and methodological innovations to connect laboratory findings with clinical decision-making, illustrating the early bench-to-bedside trajectory.

  • Clinical oncology in this era coalesced around expanding treatment modalities—radium and external beam radiotherapy, surgical classifications linked to prognosis, hormonal manipulation of prostate cancer, and early chemotherapy status, signaling a shift toward combined modality management and cancer care optimization.
  • Pathology-centric cancer research emphasized tumor biology, histological criteria, and metastasis mapping—surveys of lymphomas, minimal histologic changes for diagnosis, and metastasis incidence to adrenals and rectum, revealing early systemic patterns that shaped staging and treatment planning.
  • Hematologic malignancies and pharmacology matured into identifiable research domains, with leukemia-focused studies, folic acid antagonists, and emerging anti-cancer agent exploration, foreshadowing modern chemotherapy paradigms and pharmacotherapy in oncology.
  • Translational cancer research leveraged animal models and methodological innovations, from X-ray irradiation studies yielding ovarian tumor insights to rat tissue fixation approaches aiding treatment planning, illustrating early bench-to-bedside translation.

Influential works

These convergent trends laid the groundwork for modern oncology by establishing systemic cytotoxic strategies, endocrine therapies, and metabolism-centered research as foundational pillars. The histogenetic brain tumor taxonomy and metastasis mapping influenced neuropathology and prognosis-informed treatment paradigms. Collectively, the era anchored the integration of biology, pharmacology, and multidisciplinary care, setting the stage for subsequent advances in chemotherapy, targeted therapies, and refined cancer staging.

  • The nitrogen mustards in the palliative treatment of carcinoma (1948) introduced systemic chemotherapy for cancer, showing mustard-based agents could palliate metastatic disease, especially bronchogenic carcinoma, and spurred rapid development of cytotoxic drugs and combination regimens that transformed oncology.
  • Studies on Prostatic Cancer. I. The Effect of Castration, of Estrogen and of Androgen Injection on Serum Phosphatases in Metastatic Carcinoma of the Prostate (1941) demonstrated that hormonal manipulation could modulate disease activity and linked serum phosphatases to metastatic burden, laying groundwork for endocrine therapy.
  • The Metabolism of Tumors (1931) proposed that tumors possess distinct metabolic pathways, framing subsequent cancer energetics research and guiding the early pursuit of metabolic-targeted therapies in oncology.
  • A Classification of the Tumors of the Glioma Group on a Histogenetic Basis with a Correlated Study of Prognosis (1926) offered an early histogenetic taxonomy of brain tumors and prognosis correlations, shaping neuropathology, brain tumor classification and future research directions.

1952–1981

Genetic and Cytogenetic Oncology

Contemporary themes

Cancer began to be understood through its genetic and cytogenetic underpinnings. The two-hit hypothesis for retinoblastoma reframed cancer as a disease driven by tumor-suppressor gene inactivation, while the Philadelphia chromosome in chronic myeloid leukemia positioned cytogenetics as a diagnostic and research mainstay. Standardized classification for acute leukemias and other tumors began shaping prognosis and therapy decisions, setting the stage for molecular classifications and targeted strategies to follow.

  • Metastasis and invasion appear as the central, unifying research challenge, integrating mechanistic invasion pathways, dissemination dynamics, and prognostic invasion metrics across breast, melanoma and other cancers through experimental lines, emboli tracing, and depth of invasion studies.
  • Biomarkers and prognostic indicators guided early cancer management, with serological and receptor-based signals (CEA, embryonal globulin, estrogen receptor status) shaping diagnosis, prognosis, and therapy selection across GI, breast and hematologic cancers.
  • Therapeutic strategies reflect early systematic pharmacotherapy and agent evaluation, including adjuvant chemotherapy for breast cancer, empiric antimicrobial management of cancer patients, and early criteria/kinetics studies on curability of experimental leukemia.
  • Immunology and hematologic aspects of cancer were studied via irradiation-induced lymphopenia, immunocompetence under chemotherapy, and staging of hematologic malignancies, highlighting cancer-immunity trade-offs.
  • Classification and staging frameworks across cancers emerged early, enabling prognostic comparisons and management decisions from thyroid carcinoma and pancreatic cancer to multiple myeloma.

Influential works

These breakthroughs defined the genetic-cytogenetic paradigm that would inform decades of discovery, from tumor suppressor gene identification to the integration of cytogenetic diagnostics into routine cancer care. The identification of chromosomal abnormalities and the emphasis on standardized classification facilitated uniform diagnosis, prognosis, and treatment planning, catalyzing later advances in molecular oncology. Additionally, epidemiologic assessments of preventable cancer risks beginning in this period helped shape long-term public health prevention strategies.

  • "Mutation and Cancer: Statistical Study of Retinoblastoma" (1971) introduced the two-hit hypothesis, showing that retinoblastoma arises from inactivation of both RB gene alleles. This reframed cancer as a genetic disease with tumor-suppressor genes, guiding decades of research and RB gene discovery.
  • "A New Consistent Chromosomal Abnormality in Chronic Myelogenous Leukaemia identified by Quinacrine Fluorescence and Giemsa Staining" (1973) documented the recurring chromosomal abnormality in CML (Philadelphia chromosome), inaugurating cytogenetics as a core oncology tool and foreshadowing targeted therapy.
  • "Proposals for the Classification of the Acute Leukaemias French-American-British (FAB) Co-operative Group" (1976) established a standardized morphologic framework for acute leukemias, enabling uniform diagnosis, prognosis, and treatment choices that influenced future molecular classifications.
  • "The Causes of Cancer: Quantitative Estimates of Avoidable Risks of Cancer in the United States Today" (1981) quantified preventable cancer risks, highlighting tobacco, diet, infections, and environment, shaping prevention strategies and public health policy for decades.

1982–2002

Molecular Targeted Oncology

Contemporary themes

During 1982-2002, oncology research coalesced around a molecularly informed paradigm in which the p53 axis emerged as a central regulator of cell fate, with somatic mutations, germline alterations, and interactions with regulators like mdm-2 shaping tumor suppression, apoptosis, and treatment response across tumor types. Simultaneously, oncology embraced standardized staging, classification, imaging, and biomarker assessments, tightly linking pathology to survival outcomes and tumor heterogeneity. The era also saw the rise of genotype-guided targeted therapies, exemplified by inhibitors and monoclonal antibody strategies, alongside renewed attention to patient-centered outcomes and adaptive trial designs.

  • Central role of p53 axis in cancer biology: diverse somatic mutations, germline alterations, and interactions with regulators like mdm-2 shape tumor suppression, apoptosis, and treatment response across tumor types.
  • Methodological foundations of prognosis and research in oncology through standardized cancer staging and classification; imaging/assessment linked to survival outcomes and tumor heterogeneity across breast, lymphoid, and general cancers.
  • Theoretical shift framing cancer as a multistep, dysregulated process; foundational hallmarks concept with mechanistic links to p53/tumor suppressors illustrate network-level dysfunction driving tumorigenesis.
  • Rise of targeted molecular therapy in oncology evidenced by BCR-ABL inhibitors and clinical efficacy/safety, illustrating genotype-guided intervention in hematologic malignancies.
  • Development and validation of patient-centered outcomes and trial designs in oncology, including endocrine therapies, immunotherapy strategies, and functional outcomes measures.

Influential works

  • The Hallmarks of Cancer (2000) introduced a unifying six-hallmark framework for cancer biology, guiding research, diagnostics, and therapy with lasting influence on how tumors are studied and targeted.
  • TNM Classification of Malignant Tumours (1987) established the global staging standard, enabling consistent prognosis, treatment decisions, and trial design through the tumor-node-metastasis framework.
  • Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2 (2001) demonstrated the value of targeted therapy with trastuzumab added to chemotherapy, transforming HER2+ breast cancer outcomes.
  • A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group (1994) refined lymphoma taxonomy, improving diagnostic precision and guiding treatment decisions for lymphoid malignancies.
  • Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. (1997)

2003–2009

Biomarker-Driven Targeted Therapy

Contemporary themes

The period saw a consolidation of anti-angiogenic therapy and receptor-directed strategies as central cancer-control approaches, frequently combined with cytotoxic regimens to broaden efficacy across colorectal, breast, renal, and lung cancers. Molecular profiling and biomarker discovery introduced therapies guided by microRNA deregulation and metastasis programs, shaping decisions beyond traditional cytotoxic strategies in breast cancer and glioblastoma. Multi-agent chemotherapy regimens in metastatic disease were refined to improve outcomes, while adjuvant and early-stage integration of targeted therapies signaled a shift toward preventive-era cancer control.

  • Anti-angiogenic therapy and receptor-directed strategies consolidate as a cancer-control paradigm, combining VEGF inhibitors and EGFR/HER2–targeted agents with cytotoxic regimens to broaden efficacy across colorectal, breast, renal, and lung cancers.
  • Biomarker-driven therapy emerges from molecular profiling like microRNA deregulation and metastasis programs, guiding targeted choices and mechanistic understanding beyond cytotoxicity across breast and glioblastoma contexts.
  • Systematic evaluation and optimization of multi-agent chemo regimens in metastatic disease track regimen design evolution, exploring combinations such as FU/LV with irinotecan or oxaliplatin to improve outcomes and inform standard-of-care improvements.
  • Adjuvant and early-stage integration of targeted therapies and combination regimens signals a shift toward preventive-era cancer control, exemplified by HER2-directed therapies in breast cancer and anti-VEGFs in adjuvant contexts.
  • Global cancer epidemiology and surveillance underpin priorities in prevention, care delivery, and policy, situating diverse therapeutic advances within the broader burden and trends of cancer worldwide.

Influential works

Landmark regimens established new standards of care and reshaped practice: radiotherapy plus temozolomide for glioblastoma defined the multimodal standard of care; anti-angiogenic therapy with chemotherapy reshaped metastatic colorectal cancer management and broader solid-tumor therapy. Targeted inhibitors and biomarker-driven testing catalyzed a paradigm shift in hepatocellular carcinoma and non-small cell lung cancer, spurring routine mutation testing and biomarker-informed treatment choices. Collectively, these breakthroughs laid the groundwork for subsequent generations of combination and precision therapies and guided guidelines and drug development trajectories worldwide.

  • Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma (Stupp et al., 2005) defined the standard of care by showing that adding temozolomide to radiotherapy and continuing adjuvant temozolomide improves survival in glioblastoma, catalyzing multimodal treatment and guiding guidelines for years to come.
  • Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer (Hurwitz et al., 2004) demonstrated that adding anti-VEGF therapy to chemotherapy improves response rates and progression-free survival, inaugurating anti-angiogenic treatment in solid tumors and reshaping metastatic CRC management.
  • Sorafenib in Advanced Hepatocellular Carcinoma (Llovet et al., 2008) showed that sorafenib extends overall survival in advanced HCC, becoming the first effective systemic therapy and validating targeted kinase inhibitors in liver cancer, influencing subsequent drug development and practice.
  • Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma (2009) demonstrated that EGFR-targeted therapy can outperform standard chemotherapy in biomarker-defined NSCLC, catalyzing routine EGFR mutation testing and the shift toward biomarker-driven treatment.

2010–2016

PD-1 Driven Precision Oncology

Contemporary themes

During this period, PD-1/PD-L1 immune checkpoint blockade emerged as a unifying therapeutic paradigm across cancers, with safety and objective responses in melanoma, non-small cell lung cancer, breast cancer, and Hodgkin’s lymphoma, and evidence of durable remissions in several trials. The Hallmarks of Cancer framework provided a unifying lens that linked tumor biology, microenvironment, and therapy, enabling interpretation of diverse approaches—from oncogene-targeted agents to immunotherapies—within a common conceptual model. Biomarker-driven immunotherapy matured through predictive correlates and immune signatures that forecast response and guide patient selection and trial design, while precision oncology advanced through oncogene-targeted therapies shaping first-line and subsequent decisions.

  • PD-1/PD-L1 immune checkpoint blockade has become a unifying therapeutic paradigm across cancers, with safety and activity demonstrated in melanoma, NSCLC, breast cancer, and Hodgkin's lymphoma, and comparative efficacy against CTLA-4–biased strategies in several trials.
  • Hallmarks of Cancer (2011) provided a unifying framework that links tumor biology, microenvironment, and therapeutic targeting, helping to interpret diverse therapies—from oncogene-driven agents to immunotherapies—within a common conceptual model.
  • Biomarker-driven immunotherapy emerges through predictive correlates and immune signatures that forecast response to PD-1/PD-L1 blockade and related therapies, guiding patient selection and trial design.
  • Precision oncology is advanced by oncogene-targeted therapies (e.g., BRAF V600E in melanoma, EGFR mutations in NSCLC), illustrating how molecular profiling shapes first-line and subsequent treatment decisions.
  • Long-term safety and durability of responses characterize immune checkpoint therapies, with durable remissions and extended survival reported for ipilimumab and nivolumab across melanoma and Hodgkin's lymphoma.

Influential works

An influential update to the cancer hallmarks established a six-hallmark framework that unified cancer biology with diagnostic and therapeutic targets. Evidence that PD-1 blockade yields robust responses across mismatch-repair-deficient tumors anchored precision immunotherapy as a central paradigm. Comparisons of PD-1/PD-L1 inhibitors to chemotherapy in biomarker-defined populations established PD-L1/PD-1 guided treatment choices and reshaped first-line paradigms.

  • Hallmarks of Cancer: The Next Generation (2011) introduced an updated framework for cancer biology, codifying six hallmarks and two enabling characteristics, unifying disparate findings and guiding targeted therapies, diagnostics, and research agendas across oncology.
  • Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer demonstrated that PD-1 blockade could be safely administered with objective responses across multiple tumor types, launching the immunotherapy revolution and informing biomarker development and combination strategies.
  • PD-1 Blockade in Tumors with Mismatch-Repair Deficiency showed exquisite responses to PD-1 inhibitors in MSI-H tumors regardless of tissue origin, anchoring precision immunotherapy and routine testing for mismatch repair deficiency in cancer care.
  • Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer demonstrated superior outcomes for pembrolizumab in PD-L1-positive NSCLC and established PD-L1 expression as a clinical biomarker, reshaping first-line treatment paradigms.

2017–2017

Checkpoint-Inhibitor Guided Precision Oncology Era

Contemporary themes

Immune checkpoint blockade has become a central strategy across cancer types, with CTLA-4 and PD-1/PD-L1 inhibitors enabling combination approaches to enhance anti-tumor immunity. Genomic profiling and tumor mutational burden are increasingly used to predict response and guide precision oncology, shifting decisions from histology alone to molecular determinants. Targeted therapies and molecularly driven strategies, including HER2 blockade and ALK inhibitors, shape sequencing and resistance patterns, while foundational guidelines and population health data anchor staging, screening, and epidemiology within oncology.

  • Immune checkpoint blockade has emerged as a unifying oncologic strategy across tumor types, leveraging CTLA-4 and PD-1/PD-L1 inhibition and combinations to enhance anti-tumor immunity.
  • Genomic profiling and tumor mutational burden are increasingly used to predict response and guide precision oncology across cancers, reflecting a shift from histology alone to molecular determinants.
  • Targeted therapies and molecularly driven treatment strategies span cancer types, with HER2 blockade and ALK inhibitors informing sequencing and resistance patterns.
  • Foundational guidelines, statistics and population health data anchor clinical decision-making, staging, screening, and epidemiology in oncology.

Influential works

This period marks a transition from histology-centered decision making to biology-informed care, with durable responses and survival benefits observed across cancers. Pivotal demonstrations that immunotherapy improves outcomes and that tumor mutational burden correlates with response established biomarker-driven frameworks that guide trials and regulatory decisions. The eighth edition of the Cancer Staging Manual exemplifies the move toward integrating tumor biology with anatomical extent, bridging population data and personalized prognosis to inform treatment decisions and trial design.

  • The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging — it refines TNM criteria by integrating tumor biology with anatomical extent, enabling more precise prognosis and guiding treatment decisions and trial design.
  • Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer — PACIFIC demonstrated that consolidative durvalumab after chemoradiation significantly improves progression-free and overall survival, establishing a new standard of care for locally advanced NSCLC.
  • Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma — CheckMate 067 showed that combining nivolumab and ipilimumab improves overall survival versus monotherapy, highlighting synergy between checkpoint inhibitors and creating durable long-term responses in melanoma.
  • Tumor Mutational Burden and Response Rate to PD-1 Inhibition — This work linked higher tumor mutational burden to higher response rates to PD-1 inhibitors, establishing a biomarker framework that informs patient selection and spurs biomarker-driven trials and approvals.

2018–2024

Checkpoint-Driven Immunotherapy

Contemporary themes

In oncology during 2018-2024 the dominant paradigm centers on checkpoint-driven immunotherapy and its rapid enhancement through combination regimens across tumor types. PD-1/PD-L1 inhibitors were integrated with chemotherapy, dual checkpoint blockade, radiotherapy, and antibody-drug conjugates, with strategic use of targeted therapies to broaden frontline options. Biomarkers and tumor microenvironment features, including TGFβ-driven T cell exclusion and pan-tumor genomic signatures, increasingly guided patient selection and response prediction. Early-stage immunotherapy expansion into adjuvant and neoadjuvant settings further improved disease-free survival and pathologic responses in melanoma, non-small cell lung cancer, and breast cancer, collectively unifying research toward durable, personalized immune-based strategies.

  • Immunotherapy efficacy is being amplified by combination regimens across tumor types, including PD-1/PD-L1 inhibitors paired with chemotherapy, dual checkpoint blockade, or radiotherapy integration, evident in NSCLC, RCC, melanoma, and breast cancer trials.
  • Biomarkers and tumor microenvironment features—such as TGFβ-driven T cell exclusion, pan-tumor genomic biomarkers for PD-1 blockade, and distinct PD-1+ CD8+ T cell pools—shape and predict responses across cancers.
  • Early-stage immunotherapy expansion includes adjuvant and neoadjuvant approaches that improve disease-free survival and pathologic responses in melanoma, NSCLC, and breast cancer.
  • Strategic integration of targeted therapies and antibody-drug conjugates with immunotherapies across cancers, demonstrated by first-line NSCLC regimens with immunotherapy, TKIs as comparators, and ADCs in breast/GEJ cancers.

Influential works

  • Cancer immunotherapy using checkpoint blockade (2018) documented how blockade of immune checkpoints such as programmed death-1 (PD-1) and cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) unleashes anti-tumor immunity across cancers, catalyzing a paradigm shift from cytotoxic chemotherapy to durable immunotherapies with long-term responses.
  • Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma (2020) demonstrated that combining a programmed death-ligand 1 (PD-L1) inhibitor with anti-angiogenic therapy yields superior overall survival and progression-free survival versus sorafenib, redefining frontline therapy for unresectable HCC.
  • Lenvatinib versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma (2018) showed that lenvatinib, a multi-target tyrosine kinase inhibitor (TKI), was non-inferior to sorafenib and offered different response profiles, expanding first-line options and influencing guideline recommendations.
  • Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma (2018) reported that the PD-1 inhibitor nivolumab plus CTLA-4 inhibitor ipilimumab improved overall survival and response rates compared with standard sunitinib, establishing immunotherapy combinations as RCC standards.
  • Hallmarks of Cancer: New Dimensions (2022) extended the canonical hallmarks with new dimensions and enabling characteristics, embedding immuno-oncology, metabolism, and microenvironmental interactions into a unified framework that underpins contemporary cancer therapy development.